Cardiotoxicity

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Brana, I ^a   Tabernero, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adverse effects; Antineoplastic agents; Arrhythmia; Chemically induced heart diseases; Heart failure; QTc prolongation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; GEMCITABINE; IMATINIB; L 778123; LONAFARNIB; METHADONE; NILOTINIB; ONDANSETRON; PACLITAXEL; RAZOXANE; ROMIDEPSIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ANGINA PECTORIS; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH; SYNCOPE; THORAX PAIN;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR AGENTS; HEART DISEASES; HUMANS; INCIDENCE; ISCHEMIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78649354620     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq295     Document Type: Conference Paper

References (49)

1. Albini A, Penéis G, Donatelli F et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14-25.
2. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health condition in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
3. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
4. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009; 53: 2231-2247.
5. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
7. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
8. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-7819.
9. Serrano C, Cortes J, Russillo M et al. Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors? Eur J Cancer 2009; 7 (Suppl): 216 (Abstr 4005).
10. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344.
11. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006; 6: 1249-1269.
12. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates ERBB2-dependent Src/FAK signalling and cytoskeletal remodelling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006; 41: 228-235.
13. Baliga RR, Pimental DR, Zhao YY et al. NRG-1 induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70S6K, and MEK-MAPK-RSK. Am J Physiol Heart Circ Physiol 1999; 277: 2026-2037.
14. Perez EA, KoehlerM, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686.
15. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol 1999; 26: 60-70.
16. Grazette LP, Boecker W, Matsui T et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004; 44: 2231-2238.
17. Potts MB, Vaughn AE, McDonough H et al. Reduced Apaf-1 levels in cardiomyocytes engage a strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005; 171: 925-930.
18. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 15-16.
19. Wolf A, Couttet P, Dong M et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 2010; Epub ahead of print.
20. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
21. Demetri GD, Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
22. Chu TP, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
23. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-5212.
24. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
25. Fu HY, Minamino T, Tsukamoto O et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res 2008; 79: 600-610.
26. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
27. Chen MH, Kerkela R, Force T et al. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118: 84-95.
28. Hsieh PC, MacGillivray C, Gannon J et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114: 637-644.
29. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25: 3362-3371.
30. Ederhy S, Cohen A, Dufaitre G et al. QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol 2009; 4: 89-97.
31. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
32. Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12: 3762-3773.
33. Bello CL, Mulay M, Huang X et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009; 15: 7045-7052.
34. Tam CS, Kantarjian H, Garcia-Manero G et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112: 516-518.
35. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-3416.
36. Cooney MM, Radivoyevitch T, Dowlati A et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10: 96-100.
37. Oh Y, Herbst RS, Burris H et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008; 26: 1135-1141.
38. Tabernero J, Dirix L, Schoffski P et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. J Clin Oncol 2009; 27 (Suppl 15): Abstr 3514.
39. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191-202.
40. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
41. Sugrue MM, Yi J, Purdie D et al. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry. J Clin Oncol 2007 25 (Suppl 18): 4136.
42. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542.
43. Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5: 655-667.
44. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-399.
45. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; issue 1: CD003917.
46. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-2903.
47. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 2006; 114: 2474-2481.
48. Fernandez A, Sanguino A, Peng Z et al. An anticancer C-kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117: 4044-4054.
49. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220.